Browse TPP1

Summary
SymbolTPP1
Nametripeptidyl peptidase I
Aliases TPP I; CLN2; SCAR7; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); spinoce ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Lysosome Melanosome Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
Domain PF09286 Pro-kumamolisin
Function

Lysosomal serine protease with tripeptidyl-peptidase I activity. May act as a non-specific lysosomal peptidase which generates tripeptides from the breakdown products produced by lysosomal proteinases. Requires substrates with an unsubstituted N-terminus (By similarity).

> Gene Ontology
 
Biological Process GO:0001894 tissue homeostasis
GO:0006986 response to unfolded protein
GO:0007033 vacuole organization
GO:0007040 lysosome organization
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0034620 cellular response to unfolded protein
GO:0034976 response to endoplasmic reticulum stress
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0036498 IRE1-mediated unfolded protein response
GO:0043171 peptide catabolic process
GO:0045453 bone resorption
GO:0046849 bone remodeling
GO:0048771 tissue remodeling
GO:0048871 multicellular organismal homeostasis
GO:0050885 neuromuscular process controlling balance
GO:0050905 neuromuscular process
GO:0060249 anatomical structure homeostasis
GO:0080171 lytic vacuole organization
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0004175 endopeptidase activity
GO:0004252 serine-type endopeptidase activity
GO:0008236 serine-type peptidase activity
GO:0008238 exopeptidase activity
GO:0008240 tripeptidyl-peptidase activity
GO:0017171 serine hydrolase activity
GO:0033218 amide binding
GO:0042277 peptide binding
Cellular Component GO:0005775 vacuolar lumen
GO:0042470 melanosome
GO:0043202 lysosomal lumen
GO:0048770 pigment granule
> KEGG and Reactome Pathway
 
KEGG hsa04142 Lysosome
Reactome R-HSA-381070: IRE1alpha activates chaperones
R-HSA-392499: Metabolism of proteins
R-HSA-381119: Unfolded Protein Response (UPR)
R-HSA-381038: XBP1(S) activates chaperone genes
Summary
SymbolTPP1
Nametripeptidyl peptidase I
Aliases TPP I; CLN2; SCAR7; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); spinoce ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TPP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TPP1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29217732Lung CarcinomaPromote immunityUsing a T-cell activation assay and mixed lymphocyte reaction, TPP-1 was verified to interfere with the interaction of PD-1/PD-L1. The growth rate of tumor masses in TPP-1 or PD-L1 antibody-treated mice was 56% or 71% lower than that in control peptide-treated mice, respectively, indicating that TPP-1 inhibits, or at least retards, tumor growth. IHC of the tumors showed that IFNγ and granzyme B expression increased in the TPP-1 or PD-L1 antibody-treated groups, indicating that TPP-1 attenuates the inhibitory effect of PD-L1 on T cells and that T cells may get reactivated.
Summary
SymbolTPP1
Nametripeptidyl peptidase I
Aliases TPP I; CLN2; SCAR7; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); spinoce ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TPP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTPP1
Nametripeptidyl peptidase I
Aliases TPP I; CLN2; SCAR7; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); spinoce ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TPP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6730.0865
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.4020.668
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1370.955
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2870.34
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0950.967
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7720.794
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0480.926
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0940.968
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2470.927
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.2360.583
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7380.607
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0730.387
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TPP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTPP1
Nametripeptidyl peptidase I
Aliases TPP I; CLN2; SCAR7; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); spinoce ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TPP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTPP1
Nametripeptidyl peptidase I
Aliases TPP I; CLN2; SCAR7; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); spinoce ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TPP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TPP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTPP1
Nametripeptidyl peptidase I
Aliases TPP I; CLN2; SCAR7; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); spinoce ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TPP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTPP1
Nametripeptidyl peptidase I
Aliases TPP I; CLN2; SCAR7; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); spinoce ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TPP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTPP1
Nametripeptidyl peptidase I
Aliases TPP I; CLN2; SCAR7; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); spinoce ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TPP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTPP1
Nametripeptidyl peptidase I
Aliases TPP I; CLN2; SCAR7; ceroid-lipofuscinosis, neuronal 2, late infantile (Jansky-Bielschowsky disease); spinoce ......
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TPP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.